Latest News
Featured News
Scancell announces CFO Transition
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Scancell announces CFO Transition
Edison Report – Redesigning immunity: The next frontier in immuno-oncology
Scancell Financial Year 2026 Interim Results
H126: solid iSCIB1+ data underpins planned progress
Interim Results and Business Update
FDA clears global Phase III trial for iSCIB1+
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Notice of Interim Results and Investor Presentation
ESMO IO: Refining Standard of Care in Advanced Melanoma
CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive
SCOPE Data Update: 11 December 2025
European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London
No results found.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.